| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Innovation Management: The Quality and Quantity of the Idea Pool |
|
Digg It - Innovation Management: The Quality and Quantity of the Idea Pool
Creativity can be defined as problem identification and idea generation whilst innovation can be defined as idea s According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product election, development and commercialisation. There are distinct processes that enhance problem identification and ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in idea generation and, similarly, distinct processes that enhance idea selection, development and commercialisation. lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. Whilst there is no sure fire route to commercial success, these processes improve the probability that good ideas here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ill be generated and selected and that investment in developing and commercialising those ideas will not be wasted d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro . The quantity and quality of the idea pool is important. The Economist (2003b) states that 3000 bright ideas ar ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc needed for 100 worthwhile projects, which in turn will be winnowed down to four development programmes for new pr easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ducts. And four such development programmes are the minimum needed to stand any chance of getting one winner. Gen nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically rating a large idea pool of quality ideas is actually not that difficult. There are numerous approaches: a) One o and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ f the more useful definitions of creativity is that it is a large set of ideas, a large set of diverse ideas and l ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi rge set of novel ideas. Focusing on each of these opens up various pathways. b) Separating creative from critical ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a thinking. Creative thinking is unrestricted, uninhibited, unrestrained, imaginative, carefree, rebellious, and rev dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod lutionary. Once a large set of ideas are generated, critical thinking can be used, which is focused, feasible, con cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin servative and practical. c) One of the more useful methods is simply to be prolific. Some of the most successful tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen reations have been produced when the creator was being prolific. Being prolific trounces over the blocks that prev t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel nt output and quickly builds up competencies that are required for truly exceptional work. These topics are cover ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust d in depth in the MBA dissertation on Managing Creativity & Innovation, which can be purchased (along with a Creat y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ivity and Innovation DIY Audit, Good Idea Generator Software and Power Point Presentation) from http://www.managin . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de -creativity.com. You can also receive a regular, free newsletter by entering your email address at this site. Yo elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip are free to reproduce this article as long as no changes are made and the author's name and site URL are retained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:One Product - Service - Client Does NOT Make A Business
|